Evidence map›Paper›PMID 38693331›Full record

ArticleJournal of computer-aided molecular design2024

Reactivities of acrylamide warheads toward cysteine targets: a QM/ML approach to covalent inhibitor design.

Aaron D Danilack, Callum J Dickson, Cihan Soylu, Mike Fortunato, Stephane Rodde, Hagen Munkler, Viktor Hornak, Jose S Duca

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aaron D DanilackBiomedical Research, Novartis, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA. aaron.danilack@novartis.com.
Callum J DicksonBiomedical Research, Novartis, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Cihan SoyluBiomedical Research, Novartis, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Mike FortunatoBiomedical Research, Novartis, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA.
Stephane RoddeBiomedical Research, Novartis, Novartis Campus, 4056, Basel, Switzerland.
Hagen MunklerTechnical Research & Development, Novartis Pharma AG, Novartis Campus, 4056, Basel, Switzerland.
Viktor HornakMerck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Jose S DucaBiomedical Research, Novartis, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Covalent inhibition offers many advantages over non-covalent inhibition, but covalent warhead reactivity must be carefully balanced to maintain potency while avoiding unwanted side effects. While warhead reactivities are commonly measured with assays, a computational model to predict warhead reactivities could be useful for several aspects of the covalent inhibitor design process. Studies have shown correlations between covalent warhead reactivities and quantum mechanic (QM) properties that describe important aspects of the covalent reaction mechanism. However, the models from these studies are often linear regression equations and can have limitations associated with their usage. Applications of machine learning (ML) models to predict covalent warhead reactivities with QM descriptors are not extensively seen in the literature. This study uses QM descriptors, calculated at different levels of theory, to train ML models to predict reactivities of covalent acrylamide warheads. The QM/ML models are compared with linear regression models built upon the same QM descriptors and with ML models trained on structure-based features like Morgan fingerprints and RDKit descriptors. Experiments show that the QM/ML models outperform the linear regression models and the structure-based ML models, and literature test sets demonstrate the power of the QM/ML models to predict reactivities of unseen acrylamide warhead scaffolds. Ultimately, these QM/ML models are effective, computationally feasible tools that can expedite the design of new covalent inhibitors.

Indexed as

CysteineDrug DesignMachine LearningQuantum TheoryAcrylamideHumansLinear ModelsModels, MolecularMolecular StructureQuantitative Structure-Activity RelationshipAcrylamideCysteineAcrylamideCovalent inhibitorCovalent warheadQM/ML

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.